Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 11Withdrawn 4Unknown 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 85Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia 24Recurrence 16Lymphoma 14Myelodysplastic Syndromes 13Burkitt Lymphoma 13Congenital Abnormalities 12Lymphoma, Non-Hodgkin 10Leukemia, Monocytic, Acute 10Leukemia, Myelomonocytic, Acute 8Leukemia, Erythroblastic, Acute 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Megakaryoblastic, Acute 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Multiple Myeloma 4Hematologic Neoplasms 4Blast Crisis 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Biphenotypic, Acute 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2

Interventions

fludarabine phosphate 7Mycophenolic Acid 6Brentuximab Vedotin 6Whole-Body Irradiation 5Tacrolimus 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5Bortezomib 5Methotrexate 4Antilymphocyte Serum 4tanespimycin 3Radiotherapy 3Lenalidomide 3Filgrastim 3Etoposide 3Dasatinib 3Cyclosporine 3Cord Blood Stem Cell Transplantation 3merphos 2Vorinostat 2Vincristine 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cyproheptadine 2Carboplatin 2Busulfan 2romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large-Cell, Anaplastic × Cytarabine × Clear all
NCT00354107 2018-03-14

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 9 charts
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡